Merck CEO tells CNBC he expects breakthrough cancer vaccine will become faster to make

{
  "signal_id": "7ed37e9d-9b65-7941-e567-10f3e9d1d19d",
  "signal_type": "news",
  "signal_subtype": "expands_facilities",
  "detected_at": "2026-10-14T17:33:57+00:00",
  "company": {
    "name": "Merck",
    "domain": "merck.com"
  },
  "data": {
    "url": "https://www.cnbc.com/2026/10/14/merck-moderna-cancer-vaccine-manufacturing-time.html",
    "title": "Merck CEO tells CNBC he expects breakthrough cancer vaccine will become faster to make",
    "excerpt": "In this article Merck CEO Rob Davis told CNBC on Wednesday that he expects the company's breakthrough cancer vaccine with Moderna to get faster to manufacture over time. Shortening the current six-week timeline could potentially help the companies reach more patients. \"We are going to drive for improvement, but right now the focus really is, let's make sure we have the supply ready, we have the market ready to bring this important innovation to the market, and then we'll talk about how do we accelerate,\" he told CNBC in an exclusive interview. \"But I do think over time you're going to see that timeline shortened.\" The personalized cancer vaccine turnaround spans from sequencing a patient's tumor to delivering it to the hospital. Merck and Moderna's vaccine is designed to target the specific mutations in each individual patient's tumor rather than using a one-size-fits-all approach, which makes it complicated to produce. The idea is to train the immune system to recognize and kill those unique cancer markers and then pair that response with Merck's blockbuster immunotherapy Keytruda, which aims to help the body attack the cancer more effectively. Davis acknowledged that manufacturing the vaccine is a \"complex system,\" but said Merck and Moderna have the process \"down to a very tight science.\" \"I'm actually very confident that we're not going to have complexities in getting this...",
    "summary": "Merck officially opened a new 120,000-square-foot research and development facility named Advance on its West Point, Pennsylvania campus.",
    "location": "West Point, Pennsylvania, United States",
    "planning": false,
    "image_url": "https://image.cnbcfm.com/api/v1/image/107370990-1707414387296-gettyimages-1995499516-247a0388_agtnstai.jpeg?v=1736898742&w=1920&h=1080",
    "confidence": 0.95,
    "published_at": "2026-10-14T17:33:57Z",
    "location_data": [
      {
        "city": "West Point",
        "state": "Pennsylvania",
        "region": "Northern America",
        "country": "United States",
        "continent": "Americas",
        "fuzzy_match": false
      }
    ],
    "effective_date": "2026-10-14",
    "article_sentence": "Davis spoke to CNBC after Merck earlier Wednesday officially opened its new 120,000-square-foot research facility , which it has named Advance, in its West Point, Pennsylvania, campus."
  }
}

curl https://signals.autobound.ai/v1/signals/7ed37e9d-9b65-7941-e567-10f3e9d1d19d \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"merck.com","limit":20}'